CS Group Appoints PCAOB-Registered Auditor to Consolidate Financial Statements Across International Operations

CS Group (OTCQB: CSDX) has appointed Shah Teelani & Associates, a Dubai-based audit firm registered with the Public Company Accounting Oversight Board (PCAOB), to consolidate and audit all 2025 financial statements for the company and its subsidiaries. The engagement covers CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH, reflecting the Group's commitment to enhanced financial governance and regulatory compliance during its international expansion across the United States, GCC region, and Europe.

Management emphasized that selecting a PCAOB-registered auditor represents a significant step toward aligning the Group's financial reporting with U.S. public company standards while integrating its growing international operations under a unified framework. The consolidated audit aims to provide greater financial clarity, streamline reporting processes, and bolster investor confidence. The 2025 financial review will include operations related to the MEDUSA hygiene and disinfectant platform as well as international distribution expansion efforts.

Mohammad Essayed, Group Chief Financial Officer, stated that engaging Shah Teelani & Associates marks an important milestone in CS Group's evolution as a publicly traded company. As operations scale across multiple regions, maintaining institutional-grade standards, transparency, and regulatory compliance in financial reporting becomes essential. This appointment strengthens the governance foundation and supports the long-term growth strategy. The Group continues to focus on expanding manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.

The company's portfolio includes MEDUSA, a smart disinfectant and hygiene solutions platform expanding into wet wipes and liquid formulations for institutional and consumer use, and CS Protect-Hydrogel, a tissue spacer designed to protect healthy organs during prostate cancer radiotherapy. CSDX is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches across the GCC and Europe, diversified B2B and B2C distribution channels, global logistics agreements, and a growing intellectual property and regulatory roadmap. For further information, please visit https://group-csd.com/.